Merck & Co's cancer immunotherapy Keytruda has finally overtaken Bristol-Myers Squibb's rival Opdivo in sales - and EU regulators just rejected a new use for BMS' drug while green-lighting two new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback